Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
N/A
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$4.00M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
-19.05%
Market Cap
$3.97M
Gross Margin
0.00%
TTM Avg
41.76%
3Y Avg
-40.89%
5Y Avg
-27.26%
Market Cap
$4.43M
Gross Margin
26.32%
TTM Avg
-195.38%
3Y Avg
-178.16%
5Y Avg
-96.97%
Market Cap
$4.55M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.73M
Gross Margin
100.00%
TTM Avg
99.28%
3Y Avg
89.13%
5Y Avg
81.38%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.18M | N/A | 0.00% | 0.00% | 0.00% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.28M | 31.52% | 25.06% | 26.02% | 31.75% |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.00M | 0.00% | 0.00% | 25.00% | -19.05% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.97M | 0.00% | 41.76% | -40.89% | -27.26% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | 26.32% | -195.38% | -178.16% | -96.97% |
| CalciMedica, Inc. (CALC)vs › | $4.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.73M | 100.00% | 99.28% | 89.13% | 81.38% |
| Eocene Ltd. (EOCN)vs › | $3.52M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.83M | 19.34% | 59.23% | 54.62% | 36.41% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-04-30 | 0.00% |
| 2026-01-31 | 0.00% |
| 2025-10-31 | 0.00% |
| 2025-07-31 | 0.00% |
| 2025-04-30 | 0.00% |
| 2025-01-31 | 0.00% |
| 2024-10-31 | 0.00% |
| 2024-07-31 | 0.00% |
| 2024-04-30 | 0.00% |
| 2024-01-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
